YARROW BIOSCIENCE, INC. Stock Split Ratio
YARROW BIOSCIENCE, INC. (YARW) had Stock Split Ratio of 5.55% as of 2023-02-10, per its 10-K filed 2025-03-06.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2025-03-06
- 2023-02-10: Stockholders' Equity Note, Stock Split, Conversion Ratio 5.55%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 5.56%.
- 2021-02-12: Stockholders' Equity Note, Stock Split, Conversion Ratio 25.00%.
- 2021-02-10: Stockholders' Equity Note, Stock Split, Conversion Ratio 25.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|
| 2023-02-10 | 5.55% 10-K · filed 2025-03-06 | 5.56% 10-Q · filed 2023-05-11 |
| 2021-02-12 | 25.00% 10-K · filed 2023-03-14 | |
| 2021-02-10 | 25.00% 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |